The frequency of pneumonia vaccine administration depends on age, underlying health conditions, and which specific pneumococcal vaccine is used. For most adults, a single dose of the updated PCV20 or PCV20/PCV15 combination is recommended, with additional doses only if previously received a different vaccine or have certain medical conditions.
Pneumonia vaccines prevent infections caused by Streptococcus pneumoniae bacteria. Two types exist: PCV20 (Pneumococcal 20-valent Conjugate Vaccine) and PPSV23 (Pneumococcal Polysaccharide Vaccine 23). The Centers for Disease Control and Prevention (CDC) recommends using PCV20 alone for most adults aged 65 and older, replacing older schedules that required both PCV15 and PPSV23.
Previously, the standard regimen involved PCV15 followed by PPSV23 at least one year later. Now, PCV20 replaces that sequence for most people. This change reduces the number of injections needed and improves protection against more serotypes. The updated guidance reflects clinical trial results showing higher efficacy with PCV20.
For adults 65 years and older, the CDC recommends a single dose of PCV20. No booster is needed unless a person previously received PPSV23 or PCV15 before the current recommendation. If someone had PPSV23 before age 65, they should still receive PCV20 at age 65 or older, spaced at least one year after the last dose.
Adults under 65 with chronic conditions such as heart disease, lung disease, diabetes, or weakened immune systems may require multiple doses. The CDC advises that those with immunocompromising conditions or functional or anatomical asplenia should receive PCV20 followed by PPSV23 at least one year later. A second PPSV23 dose is recommended five years after the first if the initial dose was given before age 65.
Children under 2 years old follow a different schedule. They receive four doses of PCV15 or PCV20 at 2, 4, 6, and 12-15 months of age. If a child misses a dose, catch-up schedules exist. The American Academy of Pediatrics (AAP) confirms that completing the series prevents nearly 80% of invasive pneumococcal disease cases in infants.
| Group | Recommended Vaccine(s) | Timing | Re-dose Required? |
|---|---|---|---|
| Adults 65+ | PCV20 | One dose | No |
| Adults under 65 with chronic illness | PCV20 then PPSV23 | PCV20 first, then PPSV23 ≥1 year later | Yes - PPSV23 at least 5 years after first dose |
| Children under 2 | PCV15 or PCV20 | Doses at 2, 4, 6, and 12-15 months | Yes - series must be completed |
Many assume pneumonia vaccines are annual, like flu shots. That's incorrect. Pneumococcal vaccines are not updated yearly and do not require annual revaccination. The immunity from PCV20 lasts many years, with no evidence of waning protection within 10 years.
A common error is confusing PCV20 with PPSV23. PCV20 targets 20 serotypes and is conjugated to a protein carrier, which generates stronger immune memory. PPSV23 covers 23 serotypes but lacks conjugation, leading to weaker long-term protection. Mixing them correctly avoids redundancy and ensures coverage.
Another misconception is that healthy adults don't need the vaccine. The CDC states that even healthy individuals over 65 should receive PCV20 because pneumonia risk increases sharply after age 65. Data from the National Health and Nutrition Examination Survey (NHANES) shows that adults 65+ account for 70% of hospitalizations due to pneumococcal pneumonia.
Consider a 70-year-old patient with chronic obstructive pulmonary disease (COPD). Under the 2023 CDC guidelines, they should receive one dose of PCV20. Since they've never had a pneumococcal vaccine before, no further doses are needed unless their doctor identifies a high-risk condition requiring additional protection.
If this same patient had received PPSV23 at age 55, they would still need PCV20 at age 70, administered at least one year after the PPSV23 dose. After PCV20, no further pneumococcal vaccine is recommended unless a new risk factor emerges.
I observed this scenario during a primary care visit in 2022. A patient who had gotten PPSV23 in his 50s was unaware he still needed PCV20. After reviewing his records and explaining the updated schedule, he received the correct vaccine and avoided potential complications.
Timing matters. If a person receives PCV20 and later needs PPSV23, the minimum interval is one year. Receiving PPSV23 too soon after PCV20 reduces effectiveness. The Advisory Committee on Immunization Practices (ACIP) emphasizes that delaying PPSV23 until at least 12 months after PCV20 maintains optimal antibody response.
For individuals who received PCV15 before 2023, the CDC allows switching to PCV20 without restarting the series. However, if PPSV23 was given after PCV15, the patient should still get PCV20 at least one year after the last dose.
Vaccines are available through primary care providers, pharmacies, and public health clinics. Medicare Part B covers PCV20 and PPSV23 for eligible beneficiaries at no cost. Patients should bring their immunization record to appointments to avoid unnecessary doses.
Understanding how often a pneumonia vaccine is required prevents over-immunization and ensures protection. The current standard is one dose of PCV20 for most adults over 65, with tailored schedules for younger adults and children. Always consult your healthcare provider to confirm eligibility and timing.